Biosimilars or follow-on-biologics are the “copied” and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. 

Market Analysis and Insights: Global Biosimilars/follow-on-biologics Market
The global Biosimilars/follow-on-biologics market size is projected to reach US$ 11500 million by 2027, from US$ 9291.3 million in 2020, at a CAGR of 3.1% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biosimilars/follow-on-biologics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biosimilars/follow-on-biologics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biosimilars/follow-on-biologics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biosimilars/follow-on-biologics market.

Global Biosimilars/follow-on-biologics Scope and Market Size
Biosimilars/follow-on-biologics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilars/follow-on-biologics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Human growth hormone
Erythropoietin
Monoclonal antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Others

Segment by Application
Blood Disorders
Oncology Diseases
Chronic and Autoimmune Diseases
Growth Hormone Deficiencies
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis (Sandoz)
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck Serono (Merck)
Biogen idec
Genentech (Roche)